Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C45H53NO14 |
| Molecular Weight | 831.9006 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@H]4[C@]5(C[C@H]5C[C@H]6OC[C@@]46OC(C)=O)C1=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C7=CC=CC=C7
InChI
InChIKey=DXOJIXGRFSHVKA-BZVZGCBYSA-N
InChI=1S/C45H53NO14/c1-23-29(57-39(52)33(49)32(26-15-11-9-12-16-26)46-40(53)60-41(4,5)6)21-45(54)37(58-38(51)27-17-13-10-14-18-27)35-43(36(50)34(56-24(2)47)31(23)42(45,7)8)20-28(43)19-30-44(35,22-55-30)59-25(3)48/h9-18,28-30,32-35,37,49,54H,19-22H2,1-8H3,(H,46,53)/t28-,29+,30-,32+,33-,34-,35+,37+,43-,44+,45-/m1/s1
LAROTAXEL is a taxoid with potential antineoplastic activity. It prevents microtubule depolymerization, thereby inhibiting cell proliferation. It displays a broad spectrum of antitumor activity in vitro and in vivo, including activity against P-glycoprotein expressing tumors. LAROTAXEL was in phase III clinical trials for the treatment of breast cancer, pancreatic cancer, and bladder cancer. However, its development was discontinued.
CNS Activity
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1490
Created by
admin on Sat Dec 16 16:45:04 GMT 2023 , Edited by admin on Sat Dec 16 16:45:04 GMT 2023
|
||
|
NCI_THESAURUS |
C67437
Created by
admin on Sat Dec 16 16:45:04 GMT 2023 , Edited by admin on Sat Dec 16 16:45:04 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB36058
Created by
admin on Sat Dec 16 16:45:04 GMT 2023 , Edited by admin on Sat Dec 16 16:45:04 GMT 2023
|
PRIMARY | |||
|
TWQ8K8A81Y
Created by
admin on Sat Dec 16 16:45:04 GMT 2023 , Edited by admin on Sat Dec 16 16:45:04 GMT 2023
|
PRIMARY | |||
|
6918260
Created by
admin on Sat Dec 16 16:45:04 GMT 2023 , Edited by admin on Sat Dec 16 16:45:04 GMT 2023
|
PRIMARY | |||
|
156294-36-9
Created by
admin on Sat Dec 16 16:45:04 GMT 2023 , Edited by admin on Sat Dec 16 16:45:04 GMT 2023
|
PRIMARY | |||
|
DB12984
Created by
admin on Sat Dec 16 16:45:04 GMT 2023 , Edited by admin on Sat Dec 16 16:45:04 GMT 2023
|
PRIMARY | |||
|
8671
Created by
admin on Sat Dec 16 16:45:04 GMT 2023 , Edited by admin on Sat Dec 16 16:45:04 GMT 2023
|
PRIMARY | |||
|
C531079
Created by
admin on Sat Dec 16 16:45:04 GMT 2023 , Edited by admin on Sat Dec 16 16:45:04 GMT 2023
|
PRIMARY | |||
|
DTXSID60935420
Created by
admin on Sat Dec 16 16:45:04 GMT 2023 , Edited by admin on Sat Dec 16 16:45:04 GMT 2023
|
PRIMARY | |||
|
C48427
Created by
admin on Sat Dec 16 16:45:04 GMT 2023 , Edited by admin on Sat Dec 16 16:45:04 GMT 2023
|
PRIMARY | |||
|
LAROTAXEL
Created by
admin on Sat Dec 16 16:45:04 GMT 2023 , Edited by admin on Sat Dec 16 16:45:04 GMT 2023
|
PRIMARY | |||
|
100000128686
Created by
admin on Sat Dec 16 16:45:04 GMT 2023 , Edited by admin on Sat Dec 16 16:45:04 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
